Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study

Fig. 3

Patients with ≥ 50% and ≥ 75% reduction from baseline in MMDs over Weeks 1–12 (FAS). The 50% and 75% response variables across the three 4-week intervals are calculated as the average percentage change in MMDs (based on the available monthly values of MMDs). The comparison is based on logistic regression model including baseline MMDs as a continuous covariate, and treatment and stratification factor (monthly headache days at baseline: < 20/ ≥ 20) as factors. If the MMD value is missing for a given month, the responder status is derived based on the available values. n indicates the number of patients with observations. Data represent mean percentages. FAS, full analysis set; MMD, monthly migraine days; MRR, migraine responder rate

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us